Table 2.
Characteristics of adverse event reports of SARS-CoV-2 neutralizing monoclonal antibodies from 2020 to 2022
| Characteristics | Total n (%) | Bamlanivimab n (%) | Casirivimab/Imdevimab n (%) | Bamlanivimab/Etesevimab n (%) | Sotrovimab n (%) | Bebtelovimab n (%) | Tixagevimab/Cilgavimab n (%) |
|---|---|---|---|---|---|---|---|
| Number of reports | 42,642 (100) | 15,403 (36.1) | 15,252 (35.8) | 2913 (6.8) | 4487 (10.5) | 1355 (3.2) | 3232 (7.6) |
| Age, years | |||||||
| Under 20 | 864 (2.0) | 173 (1.1) | 450 (3.0) | 122 (4.2) | 59 (1.3) | 27 (2.0) | 33 (1.0) |
| 20 ~ 39 | 5758 (13.5) | 1117 (7.3) | 2892 (19.0) | 786 (27.0) | 585 (13.0) | 222 (16.4) | 156 (4.8) |
| 40 ~ 59 | 9802 (23.0) | 3157 (20.5) | 4402 (28.9) | 1000 (34.3) | 320 (7.1) | 304 (22.4) | 619 (19.2) |
| 60 ~ 79 | 14,215 (33.3) | 6993 (45.4) | 4585 (30.1) | 833 (28.6) | 472 (10.5) | 398 (29.4) | 934 (28.9) |
| Over 80 | 4154 (9.7) | 2305 (15.0) | 1294 (8.5) | 123 (4.2) | 179 (4.0) | 121 (8.9) | 132 (4.1) |
| Unknown | 7849 (18.4) | 1658(10.8) | 1629 (10.7) | 49 (1.7) | 2872 (64.0) | 283 (20.9) | 1358 (42.0) |
| Gender | |||||||
| Male | 16,896 (39.6) | 7552 (49.0) | 5947 (39.0) | 1087 (37.3) | 549 (12.2) | 408 (30.1) | 1353 (41.9) |
| Female | 20,868 (48.9) | 7564 (49.1) | 7861 (51.5) | 1723 (59.1) | 1197 (26.7) | 858 (63.3) | 1665 (51.5) |
| Unknown | 4878 (11.4) | 287 (1.9) | 1444 (9.5) | 103 (3.5) | 2741 (61.1) | 89 (6.6) | 214 (6.6) |